Welcome to our dedicated page for Abeona Therapeut news (Ticker: ABEO), a resource for investors and traders seeking the latest updates and insights on Abeona Therapeut stock.
Abeona Therapeutics Inc. (Nasdaq: ABEO) is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, with a primary focus on recessive dystrophic epidermolysis bullosa (RDEB)ZEVASKYN® (prademagene zamikeracel), which Abeona describes as the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with RDEB.
On this page, readers can follow ABEO news related to ZEVASKYN’s commercial rollout, including activation of new Qualified Treatment Centers, initial patient treatments, and updates on manufacturing and product release processes at the company’s cell and gene therapy cGMP facility in Cleveland, Ohio. Press releases also cover developments in reimbursement and market access, such as the assignment of a permanent HCPCS J-code (J3389) by the Centers for Medicare and Medicaid Services (CMS) and coverage decisions by commercial health plans.
Abeona’s news flow additionally features corporate and pipeline updates, including quarterly financial results, participation in investor conferences, and progress in its AAV-based gene therapy programs, such as the ABO-503 program for X-linked retinoschisis (XLRS) selected for the FDA’s Rare Disease Endpoint Advancement Pilot Program. Management appointments and employee equity inducement grants under Nasdaq Listing Rule 5635(c)(4) are also regular topics.
Investors, clinicians, and other stakeholders can use this ABEO news feed to review the company’s latest disclosures on commercial performance indicators, regulatory and payer milestones, treatment site expansion, and strategic pipeline initiatives in gene therapy.
Abeona Therapeutics reported its full year 2024 financial results and provided updates on pz-cel regulatory progress. The FDA's priority review of pz-cel BLA is advancing with a PDUFA date of April 29, 2025, with the company targeting first patient treatment in Q3 2025 if approved.
Financial highlights include cash position of $98.1 million as of December 31, 2024, up from $52.6 million year-over-year. The company reported a net loss of $63.7 million ($1.55 per share) compared to $54.2 million ($2.53 per share) in 2023. R&D expenses increased to $34.4 million from $31.1 million, while G&A expenses rose to $29.9 million from $19.0 million.
The company has secured additional facility space in Cleveland for manufacturing expansion and obtained two patents extending protection for pz-cel treatment to 2037 and transport system to 2040. Current cash runway is expected to fund operations into 2026.
Abeona Therapeutics (Nasdaq: ABEO) has announced its participation in the upcoming Leerink Partners Global Healthcare Conference in Miami, Florida. The company's CEO, Vish Seshadri, Ph.D., M.B.A., will deliver a presentation on Monday, March 10, 2025, at 3:00 p.m. Eastern Time.
Investors and interested parties can access a live webcast of the presentation through the 'Events' section of Abeona's investor relations website at https://investors.abeonatherapeutics.com/events. The presentation recording will remain available for replay on the website for 30 days following the event.
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to five new non-executive employees. The awards, approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4) on February 28, 2025, consist of an aggregate of 16,300 restricted shares of Abeona common stock.
The restricted stock awards feature a three-year vesting schedule, with one-third of the shares vesting annually on each anniversary of the Grant Date. Full vesting will occur on the third anniversary, contingent upon continued employment with Abeona.
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to eight new non-executive employees. The Compensation Committee approved these inducement grants on January 31, 2024, consisting of a total of 13,000 restricted shares of common stock. The equity awards were granted in compliance with Nasdaq Listing Rule 5635(c)(4).
The vesting schedule for these restricted stock awards is structured over three years, with one-third of the shares vesting annually on each grant date anniversary. Full vesting will occur on the third anniversary of the Grant Date, contingent upon continued employment with Abeona.
Abeona Therapeutics (Nasdaq: ABEO) has granted equity awards to five new non-executive employees as employment inducement. The awards, approved under Nasdaq Listing Rule 5635(c)(4), consist of a total of 28,600 restricted shares of common stock. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent upon continued employment. The Compensation Committee of Abeona's Board of Directors approved these awards on December 30, 2024.
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to nine new non-executive employees. The awards, approved under Nasdaq Listing Rule 5635(c)(4), consist of 44,700 restricted shares of Abeona common stock. The shares will vest in three equal annual installments, with full vesting occurring on the third anniversary of the Grant Date, contingent upon continued employment. The equity awards were approved by the Compensation Committee of Abeona's Board of Directors on November 30, 2024, as material inducement to employment.
Abeona Therapeutics reported Q3 2024 financial results and corporate updates. The FDA accepted their BLA resubmission for pz-cel in recessive dystrophic epidermolysis bullosa, setting a PDUFA date of April 29, 2025. The company's cash position was $110.0 million as of September 30, 2024. Q3 net loss was $30.3 million, with R&D expenses of $8.9 million and G&A expenses of $6.4 million. CMS granted a product-specific procedure code for pz-cel and assigned it to Pre-MDC MS-DRG 018. The company secured new patents for pz-cel treatment and expanded its Cleveland facility for manufacturing capacity.
Abeona Therapeutics announced that the FDA has accepted its resubmitted Biologics License Application (BLA) for pz-cel, an investigational autologous cell-based gene therapy for recessive dystrophic epidermolysis bullosa (RDEB). The FDA set a PDUFA target action date of April 29, 2025. The BLA resubmission includes clinical data from the Phase 3 VIITAL™ study and a Phase 1/2a study with up to 8 years of follow-up. If approved, pz-cel would be the first autologous, cell-based gene therapy for RDEB, designed to provide collagen VII expression through COL7A1 gene integration.
Abeona Therapeutics (Nasdaq: ABEO) announced its management team's participation in two upcoming investor conferences in November 2024. The company will attend the Truist Securities BioPharma Symposium for investor meetings on November 7, and the Stifel 2024 Healthcare Conference on November 18, which includes a fireside chat at 4:10 p.m. ET and investor meetings. A live webcast of the fireside chat will be available on Abeona's website investor section, with a replay available for a time.
Abeona Therapeutics (Nasdaq: ABEO) has announced new equity awards for nine recently hired non-executive employees. The Compensation Committee approved restricted stock awards totaling 27,500 shares of common stock as employment inducements. These awards will vest over three years, with one-third of the shares vesting annually on the grant date anniversary. Full vesting will occur on the third anniversary, contingent on continued employment.